vs
ADMA BIOLOGICS, INC.（ADMA）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是ADMA BIOLOGICS, INC.的1.4倍（$200.5M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 2.2%，领先33.2%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 5.2%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $1.1M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs -3.3%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ADMA vs ROG — 直观对比
营收规模更大
ROG
是对方的1.4倍
$139.2M
营收增速更快
ADMA
高出13.1%
5.2%
净利率更高
ADMA
高出33.2%
2.2%
自由现金流更多
ADMA
多$33.5M
$1.1M
两年增速更快
ADMA
近两年复合增速
-3.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $200.5M |
| 净利润 | $49.4M | $4.5M |
| 毛利率 | 63.8% | 32.2% |
| 营业利润率 | 45.1% | — |
| 净利率 | 35.5% | 2.2% |
| 营收同比 | 18.4% | 5.2% |
| 净利润同比 | -55.9% | 421.4% |
| 每股收益（稀释后） | $0.20 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $139.2M | $201.5M | ||
| Q3 25 | $134.2M | $216.0M | ||
| Q2 25 | $122.0M | $202.8M | ||
| Q1 25 | $114.8M | $190.5M | ||
| Q4 24 | $117.5M | $192.2M | ||
| Q3 24 | $119.8M | $210.3M | ||
| Q2 24 | $107.2M | $214.2M |
净利润ADMAROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | $49.4M | $4.6M | ||
| Q3 25 | $36.4M | $8.6M | ||
| Q2 25 | $34.2M | $-73.6M | ||
| Q1 25 | $26.9M | $-1.4M | ||
| Q4 24 | $111.9M | $-500.0K | ||
| Q3 24 | $35.9M | $10.7M | ||
| Q2 24 | $32.1M | $8.1M |
毛利率ADMAROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 63.8% | 31.5% | ||
| Q3 25 | 56.3% | 33.5% | ||
| Q2 25 | 55.1% | 31.6% | ||
| Q1 25 | 53.2% | 29.9% | ||
| Q4 24 | 53.9% | 32.1% | ||
| Q3 24 | 49.8% | 35.2% | ||
| Q2 24 | 53.6% | 34.1% |
营业利润率ADMAROG
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 3.5% | ||
| Q3 25 | 38.0% | 7.3% | ||
| Q2 25 | 35.1% | -33.3% | ||
| Q1 25 | 30.4% | -0.2% | ||
| Q4 24 | 32.6% | -6.6% | ||
| Q3 24 | 33.1% | 6.9% | ||
| Q2 24 | 36.6% | 5.3% |
净利率ADMAROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | 35.5% | 2.3% | ||
| Q3 25 | 27.1% | 4.0% | ||
| Q2 25 | 28.1% | -36.3% | ||
| Q1 25 | 23.4% | -0.7% | ||
| Q4 24 | 95.2% | -0.3% | ||
| Q3 24 | 30.0% | 5.1% | ||
| Q2 24 | 29.9% | 3.8% |
每股收益（稀释后）ADMAROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.20 | $0.20 | ||
| Q3 25 | $0.15 | $0.48 | ||
| Q2 25 | $0.14 | $-4.00 | ||
| Q1 25 | $0.11 | $-0.08 | ||
| Q4 24 | $0.45 | $-0.04 | ||
| Q3 24 | $0.15 | $0.58 | ||
| Q2 24 | $0.13 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $195.8M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $1.2B |
| 总资产 | $624.2M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $87.6M | $197.0M | ||
| Q3 25 | $61.4M | $167.8M | ||
| Q2 25 | $90.3M | $157.2M | ||
| Q1 25 | $71.6M | $175.6M | ||
| Q4 24 | $103.1M | $159.8M | ||
| Q3 24 | $86.7M | $146.4M | ||
| Q2 24 | $88.2M | $119.9M |
总债务ADMAROG
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ADMAROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $477.3M | $1.2B | ||
| Q3 25 | $431.2M | $1.2B | ||
| Q2 25 | $398.3M | $1.2B | ||
| Q1 25 | $373.4M | $1.3B | ||
| Q4 24 | $349.0M | $1.3B | ||
| Q3 24 | $231.9M | $1.3B | ||
| Q2 24 | $188.3M | $1.3B |
总资产ADMAROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $624.2M | $1.4B | ||
| Q3 25 | $568.7M | $1.4B | ||
| Q2 25 | $558.4M | $1.5B | ||
| Q1 25 | $510.6M | $1.5B | ||
| Q4 24 | $488.7M | $1.5B | ||
| Q3 24 | $390.6M | $1.5B | ||
| Q2 24 | $376.4M | $1.5B |
负债/权益比ADMAROG
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $1.1M |
| 自由现金流率自由现金流/营收 | 24.8% | 0.5% |
| 资本支出强度资本支出/营收 | 0.8% | 2.3% |
| 现金转化率经营现金流/净利润 | 0.72× | 1.29× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $70.1M |
8季度趋势，按日历期对齐
经营现金流ADMAROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $35.6M | $46.9M | ||
| Q3 25 | $13.3M | $28.9M | ||
| Q2 25 | $21.1M | $13.7M | ||
| Q1 25 | $-19.7M | $11.7M | ||
| Q4 24 | $50.2M | $33.7M | ||
| Q3 24 | $25.0M | $42.4M | ||
| Q2 24 | $45.6M | $22.9M |
自由现金流ADMAROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $34.6M | $42.2M | ||
| Q3 25 | $-1.1M | $21.2M | ||
| Q2 25 | $18.7M | $5.6M | ||
| Q1 25 | $-24.4M | $2.1M | ||
| Q4 24 | $47.5M | $18.3M | ||
| Q3 24 | $24.0M | $25.2M | ||
| Q2 24 | $43.6M | $8.8M |
自由现金流率ADMAROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 24.8% | 20.9% | ||
| Q3 25 | -0.8% | 9.8% | ||
| Q2 25 | 15.3% | 2.8% | ||
| Q1 25 | -21.2% | 1.1% | ||
| Q4 24 | 40.4% | 9.5% | ||
| Q3 24 | 20.0% | 12.0% | ||
| Q2 24 | 40.7% | 4.1% |
资本支出强度ADMAROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 0.8% | 2.3% | ||
| Q3 25 | 10.7% | 3.6% | ||
| Q2 25 | 2.0% | 4.0% | ||
| Q1 25 | 4.1% | 5.0% | ||
| Q4 24 | 2.3% | 8.0% | ||
| Q3 24 | 0.9% | 8.2% | ||
| Q2 24 | 1.9% | 6.6% |
现金转化率ADMAROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | 0.72× | 10.20× | ||
| Q3 25 | 0.36× | 3.36× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | 3.96× | ||
| Q2 24 | 1.42× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
ROG
暂无分部数据
